奥拉帕利维持治疗新诊断BRCA突变晚期卵巢癌:SOLO1/GOG 3004 5年随访
SOLO1是一项随机双盲安慰剂对照3期试验,纳入新诊断BRCA突变晚期高级别浆液性或子宫内膜样卵巢癌患者,铂类化疗后临床完全或部分缓解者按2:1随机接受奥拉帕利300mg每日两次或安慰剂维持治疗最多2年。
要点
- 最常见3-4级不良事件为贫血(22% vs 2%)和中性粒细胞减少(8% vs 5%)。
核心结论
- 结果支持奥拉帕利维持治疗作为该人群的标准治疗。
研究设计与样本
- SOLO1/GOG 3004为随机、双盲、安慰剂对照3期试验,在15个国家118个中心开展。
- 纳入≥18岁、ECOG 0-1、BRCA突变、新诊断晚期高级别浆液性或子宫内膜样卵巢癌、铂类化疗后完全或部分临床缓解的患者。
- 按2:1随机接受奥拉帕利300mg每日两次或安慰剂口服维持治疗最多2年,按铂类化疗后临床缓解分层。
- 主要终点为研究者评估的无进展生存期,疗效分析采用意向治疗人群。
- 260例随机至奥拉帕利组,131例至安慰剂组;本次更新事后分析数据截止2020年3月5日。
主要发现
- 最常见3-4级不良事件为贫血(奥拉帕利组57/260例[22%] vs 安慰剂组2/130例[2%])和中性粒细胞减少(22例[8%] vs 6例[5%])。
- 严重不良事件发生于奥拉帕利组55/260例(21%)和安慰剂组17/130例(13%);研究治疗期间或停药后30天内无治疗相关不良事件导致死亡。
关键数值与推荐
- 奥拉帕利300mg每日两次口服维持治疗最多2年。
- 3-4级贫血发生率奥拉帕利组22%(57/260)vs 安慰剂组2%(2/130)。
- 3-4级中性粒细胞减少发生率奥拉帕利组8%(22/260)vs 安慰剂组5%(6/130)。
- 严重不良事件发生率奥拉帕利组21%(55/260)vs 安慰剂组13%(17/130)。
临床怎么用
- 对新诊断BRCA突变晚期高级别浆液性或子宫内膜样卵巢癌、铂类化疗后缓解的患者,可考虑奥拉帕利300mg每日两次维持治疗最多2年。
- 治疗期间需监测贫血和中性粒细胞减少等血液学毒性。
- 奥拉帕利维持治疗的PFS获益在停药后仍持续,支持其作为该人群标准治疗。
局限性
- 本次为事后分析,非预设主要分析。
- 无进展生存期为研究者评估。
- 总生存数据未在本文报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is a high unmet need for treatment regimens that increase the chance of long-term remission and possibly cure for women with newly diagnosed advanced ovarian cancer. In the primary analysis of SOLO1/GOG 3004, the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib significantly improved progression-free survival versus placebo in patients with a BRCA mutation; median progression-free survival was not reached. Here, we report an updated, post-hoc analysis of progression-free survival from SOLO1, after 5 years of follow-up. METHODS: SOLO1 was a randomised, double-blind, placebo-controlled, phase 3 trial, done across 118 centres in 15 countries, that enrolled patients aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0-1 and with BRCA-mutated, newly diagnosed, advanced, high-grade serous or endometrioid ovarian cancer with a complete or partial clinical response after platinum-based chemotherapy. Patients were randomly assigned (2:1) via a web-based or interactive voice-response system to receive olaparib (300 mg twice daily) or placebo tablets orally as maintenance monotherapy for up to 2 years; randomisation was by blocks and was stratified according to clinical response after platinum-based chemotherapy. Patients, treatment providers, and data assessors were masked to group assignment. The primary endpoint was investigator-assessed progression-free survival. Efficacy is reported in the intention-to-treat population and safety in patients who received at least one dose of treatment. The data cutoff for this updated, post-hoc analysis was March 5, 2020. This trial is registered with ClinicalTrials.gov (NCT01844986) and is ongoing but closed to new participants. FINDINGS: Between Sept 3, 2013, and March 6, 2015, 260 patients were randomly assigned to olaparib and 131 to placebo. The median treatment duration was 24·6 months (IQR 11·2-24·9) in the olaparib group and 13·9 months (8·0-24·8) in the placebo group; median follow-up was 4·8 years (2·8-5·3) in the olaparib group and 5·0 years (2·6-5·3) in the placebo group. In this post-hoc analysis, median progression-free survival was 56·0 months (95% CI 41·9-not reached) with olaparib versus 13·8 months (11·1-18·2) with placebo (hazard ratio 0·33 [95% CI 0·25-0·43]). The most common grade 3-4 adverse events were anaemia (57 [22%] of 260 patients receiving olaparib vs two [2%] of 130 receiving placebo) and neutropenia (22 [8%] vs six [5%]), and serious adverse events occurred in 55 (21%) of 260 patients in the olaparib group and 17 (13%) of 130 in the placebo group. No treatment-related adverse events that occurred during study treatment or up to 30 days after discontinuation were reported as leading to death. No additional cases of myelodysplastic syndrome or acute myeloid leukaemia were reported since the primary data cutoff, including after the 30-day safety follow-up period. INTERPRETATION: For patients with newly diagnosed advanced ovarian cancer and a BRCA mutation, after, to our knowledge, the longest follow-up for any randomised controlled trial of a PARP inhibitor in this setting, the benefit derived from 2 years' maintenance therapy with olaparib was sustained beyond the end of treatment, extending median progression-free survival past 4·5 years. These results support the use of maintenance olaparib as a standard of care in this setting. FUNDING: AstraZeneca; Merck Sharpe & Dohme, a subsidiary of Merck & Co, Kenilworth, NJ, USA.
引用
- Banerjee S, Moore KN, Colombo N, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021. PMID: 34715071. doi:10.1016/S1470-2045(21)00531-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。